Navigation Links
Bionovo Reports Second Quarter 2008 Financial Results
Date:8/5/2008

EMERYVILLE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced results for the second quarter of 2008.

Quarter Results

The company did not report any revenue for the three and six months ended June 30, 2008. Revenues were $3,750 and $7,500 for the three and six months ended June 30, 2007, respectively, received from a licensing and technology transfer agreement with a Taiwanese company. In October of 2007, we terminated the agreement following notice of material breach by the other party and recognized the remaining deferred revenue of $91,250 in December 2007.

Total operating expenses for the three and six months ending June 30, 2008 were $4.4 million and $8.6 million, respectively, compared to $2.8 million and $6.3 million, respectively, for the same period in 2007.

The Company reported a net loss for the three and six months ended June 30, 2008 of $4.2 million, or $0.06 per share, and $8.2 million, or $0.11 per share, respectively, compared with a net loss of $2.7 million, or $0.04 per share, and $6.0 million, or $0.09 per share, respectively, for the same periods in 2007.

The Company ended the quarter with $24.6 million in cash, cash equivalents and short term investments, and began the quarter with $29.2 million, a difference of $4.6 million.

Company Highlights

-- The Phase 1 portion of the BZL101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues successfully, demonstrating both positive safety and tolerability profiles, as well as the early signs of efficacy.

-- Bionovo presented data on two additional preclinical anti-cancer drug candidates -- BN107 and BN108 -- at the American Association of Cancer Research (AACR) conf
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
(Date:9/17/2014)... Shimadzu Scientific Instruments introduces ... which offers a powerful separation method for ... provides a new level of knowledge and ... to scientists analyzing pharmaceutical impurities, proteins, lipids, ... Comprehensive 2D-LC combines two independent separation modes ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... , Sept. 17, 2014 BioClinica®, Inc., a ... Solutions, today announced three of its experts are speaking ... Clinical Data Management to be held September 28 to ... . The Company also announced the innovative Compass ... quality in clinical trials acquired earlier this year, is ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... N.J., Sept. 22, 2011 Parent ... in the United States focused on finding a cure for ... awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at ... Duchenne Grant for $98,000. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ...
... PrimeraDx today announced that Albert Luderer has been appointed ... CEO Matthew McManus commented:  "We are excited to have Al ... launched the ICE Plex System, which is the first ... qPCR, and Al brings many years of experience in the ...
... Neogen Corporation (NASDAQ: NEOG ) has developed ... considered by many to be the most potent, naturally-occurring carcinogen. ... wide range of commodities, including corn. Because it is a ... 100 countries have established regulatory limits for aflatoxin in commodities ...
Cached Biology Technology:Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 2Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvania's Dr. Tejvir S. Khurana 3PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Neogen Launches Fully Quantitative Lateral Flow Test for Aflatoxin 2
(Date:9/17/2014)... human retinoblastoma protein gene are a leading cause of ... to fruit fly eyes to unlock the secrets of ... featured on the cover of the current issue of ... University researchers provide the first detailed examination of a ... human cancer gene, said Irina Pushel, MSU undergraduate and ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... social behavior by studying nonhuman mammals and primates, but ... their unusually large brains relative to their body size ... environment---not merely in a large population of cooperating creatures, ... setting of alliances and competitors. The same is true ... social carnivores, like hyenas and lions. , A new ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... deadline for the European Congress on Osteoporosis & Osteoarthritis ... Thursday January 17, 2013. SUBMIT YOUR ABSTRACT ... yet registered?, Register now for Europe,s largest and most ... April 17-20, 2013. Featuring renowned speakers, ...
... With $14 million from the William & Nancy ... of Orange County, UC Irvine is helping lead the ... 88 children in the U.S. autism., The funding ... Southern California, which will provide unparalleled access to assessment, ...
... ornamental fish industry faces a global problem with antibiotic ... for fish diseases may not work when needed ... antibiotic-resistant bacteria. The risk to humans is probably ... compromised immune systems, researchers said, although transmission of disease ...
Cached Biology News:UCI research turns the corner on autism 2UCI research turns the corner on autism 3Ornamental fish industry faces increasing problems with antibiotic resistance 2Ornamental fish industry faces increasing problems with antibiotic resistance 3
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
Green Standard is fluorescein....
Human/Mouse/Rat LAR Affinity Purified PAb...
Biology Products: